polycystin family receptor for egg jellyGenealiases: []
Q-omics provides the consensus-scored PKDREJ profile across patient tissues and cancer cell-line models. PKDREJ expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PKDREJ is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PKDREJ RNA expression shows 17,946 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where PKDREJ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKDREJ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKDREJ survival associations across molecular data types. PKDREJ RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKDREJ RNA expression–survival associations across cancer types. High PKDREJ expression shows unfavorable associations in ACC, but favorable associations in HNSC, KIRC, UCS, PAAD and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PKDREJ RNA expression.
This table summarizes PKDREJ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PKDREJ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKDREJ shows lower tumor expression in THCA, KICH, BRCA and UCEC and higher tumor expression in LIHC and LUSC. The THCA box plot shows higher PKDREJ RNA expression in normal versus tumor tissue (log2 FC = −0.312, t-test p < 0.001).
This table shows molecular features associated with PKDREJ in patient tissues and cancer cell lines. In patient samples, PKDREJ shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PKDREJ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
